-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Extracellular vesicles (EVs) play an important role in a variety of physiological and pathological processes in the body.
Figure 1.
EVs antibody selection and labeling methods
Figure 2.
In addition to antibody tags, unconjugated antibodies also had an effect on the positive rate of EVs
Figure 3.
Direct detection of EVs in cell supernatants
The cases introduced above are all based on the analysis of pure EVs, the content of impurity particles is very low, and the impact on the measurement results is relatively small
Figure 4.
Compared with F-NTA, nFCM can also utilize a multicolor fluorescent labeling strategy to characterize sEV subsets
Figure 5.
in conclusion
To sum up, the R&D team of Lonza Group conducted a comprehensive comparison of various indicators in the process of EVs fluorescent labeling, and conducted research on the selection of dyes in the process of EVs purity determination, protein marker analysis, and characterization of EVs in complex systems.
The author affirmed the accuracy and sensitivity of nFCM for EVs detection, and proposed a method for EVs purity characterization.
Figure 6.
appendix:
Lonza Walkersville (Lonza Group) is a leading global CDMO enterprise, a global multinational company dominated by life sciences and leading in biochemistry, fine chemicals, functional chemistry and other industries.
Figure 7.
Lonza has currently purchased 3 NanoFCMs, which are used for EVs R&D, production quality control and CRO projects respectively.
They are committed to the large-scale production, purification and characterization of EVs, and will be used in the field of EVs drug delivery in the future
.
In November 2021, Lonza acquired Codiak's exosome production site in Lexington, Massachusetts, officially becoming a strategic manufacturing partner for Codiak's pipeline
.
At that time, Lonza will use Codiak's high-throughput exosome production technology to provide services to third parties and develop advanced exosome products to help the cell and gene therapy industry
.
references:
- Fortunato D, Mladenović D, Criscuoli M, et al.
Opportunities and Pitfalls of Fluorescent Labeling Methodologies for Extracellular Vesicle Profiling on High-Resolution Single-Particle Platforms[J].
International Journal of Molecular Sciences, 2021, 22(19): 10510.
